ClinicalTrials.gov
ClinicalTrials.gov Menu

Vaccine Therapy in Treating Patients With Unresectable Metastatic Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00004148
Recruitment Status : Completed
First Posted : February 20, 2004
Last Update Posted : February 11, 2013
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)

December 10, 1999
February 20, 2004
February 11, 2013
October 1999
April 2006   (Final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00004148 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Vaccine Therapy in Treating Patients With Unresectable Metastatic Melanoma
A Phase I Trial of Intra Lesional RV-B7.1 Vaccine in the Treatment of Malignant Melanoma
Phase I trial to study the effectiveness of vaccine therapy in treating patients who have unresectable metastatic melanoma. Vaccines may make the body build an immune response to kill tumor cells.

OBJECTIVES:

I. Determine the maximum tolerated dose of the rV-B7.1 vaccine that elicits a host immune response and is associated with acceptable toxicity in patients with malignant metastatic melanoma.

II. Determine all clinical toxicities associated with this regimen in this patient population.

III. Determine the safety of this regimen in this patient population. IV. Assess evidence of host antimelanoma immune reactivity following this regimen.

V. Determine the effect of this regimen on T-cell immunity. VI. Assess the clinical response in this patient population receiving this regimen.

VII. Evaluate quality of life of these patients during this regimen.

OUTLINE: This is a dose escalation study.

Patients receive rV-B7.1 intralesionally every 4 weeks for 8 weeks (weeks 0, 4, and 8). Treatment continues every 12 weeks in the absence of unacceptable toxicity or disease progression for up to 2 courses. Cohorts of 6-8 patients receive escalating doses of vaccine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 or 3 of 8 patients experience dose limiting toxicities.

Quality of life is assessed before treatment, every 4 weeks, and at end of treatment. Patients are followed every 3 months.

Interventional
Phase 1
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Melanoma (Skin)
Biological: recombinant vaccinia-B7.1 vaccine
Experimental: Arm I
Patients receive rV-B7.1 intralesionally every 4 weeks for 8 weeks (weeks 0, 4, and 8). Treatment continues every 12 weeks in the absence of unacceptable toxicity or disease progression for up to 2 courses. Cohorts of 6-8 patients receive escalating doses of vaccine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 or 3 of 8 patients experience dose limiting toxicities.
Intervention: Biological: recombinant vaccinia-B7.1 vaccine

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
12
Not Provided
Not Provided
April 2006   (Final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Histologically proven metastatic, unresectable melanoma Dermal, subcutaneous, or lymph node metastases
  • Accessible for injection
  • Lesions must measure at least 1 cm
  • Patients with no prior treatment allowed
  • Patients must have one of the following as proof of prior vaccinia immunization:

    • Physician certification
    • Recollection and appropriate vaccination scar site
    • No encephalitis, untreated cerebral metastases, other structural brain lesions, or leptomeningeal disease
    • No ascites or pleural effusions
    • No leukemia or lymphoma

PATIENT CHARACTERISTICS:

  • Age: Over 18
  • Performance status: ECOG 0-1 Karnofsky 80-100%
  • Life expectancy: Greater than 3 months
  • WBC greater than 4,000/mm3
  • Platelet count greater than 100,000/mm3
  • Hemoglobin greater than 10g/dL
  • Bilirubin less than 1.5 mg/dL
  • Transaminases no greater than 2 times upper limit of normal (ULN)
  • Alkaline phosphatase no greater than 2 times ULN
  • PT/PTT no greater than 2 fold elevation in patients not receiving anticoagulation medications
  • No alcoholic cirrhosis
  • Creatinine less than 2.0 mg/dL OR creatine clearance greater than 60 mL/min
  • No congestive heart failure
  • No serious cardiac arrhythmias
  • No recent prior myocardial infarction
  • No clinical coronary artery disease
  • No chronic obstructive pulmonary disease
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No seizure disorders
  • No underlying immunosuppressive disorder
  • No autoimmune disease HIV negative
  • No skin diseases
  • No open wounds
  • No eczema or other contraindications to vaccinia virus administration
  • Patients must be able to avoid high risk individuals (e.g., immunosuppressed patients, children under 3 years, pregnant women, patients with active or a history of eczema, or patients with other skin conditions) for 7-10 days following treatment
  • No significant allergy or hypersensitivity to eggs
  • No active or chronic infections
  • No concurrent medical illness
  • No other significant medical disease which would increase risk to patient
  • No other prior malignancy within the past 5 years except stage I carcinoma of the cervix or basal cell carcinoma

PRIOR CONCURRENT THERAPY:

  • At least 8 weeks since prior immunotherapy and recovered
  • No prior live pox virus vector
  • No more than 2 prior chemotherapy regimens
  • At least 4 weeks since prior chemotherapy and recovered
  • At least 4 weeks since prior systemic corticosteroids
  • No systemic corticosteroids for concurrent illness
  • No concurrent immunosuppressive steroids
  • At least 2 weeks since prior radiotherapy and recovered (no bone marrow toxicity)
  • At least 6 months since prior radiotherapy for brain metastases and recovered
  • At least 4 weeks since prior surgery for management of the primary or metastatic lesions and recovered with remaining measurable disease
  • At least 6 months since prior surgery for brain metastases and recovered
  • No concurrent immunosuppressive drugs
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00004148
CDR0000067380
AECM-99-101
NCI-T99-0006
Not Provided
Not Provided
Not Provided
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Not Provided
Study Chair: Howard L. Kaufman, MD Albert Einstein College of Medicine, Inc.
National Cancer Institute (NCI)
June 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP